554 related articles for article (PubMed ID: 16049491)
1. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
Sengupta S; Eavarone D; Capila I; Zhao G; Watson N; Kiziltepe T; Sasisekharan R
Nature; 2005 Jul; 436(7050):568-72. PubMed ID: 16049491
[TBL] [Abstract][Full Text] [Related]
2. Cancer: one step at a time.
Mooney D
Nature; 2005 Jul; 436(7050):468-9. PubMed ID: 16049458
[No Abstract] [Full Text] [Related]
3. Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
Kohandel M; Haselwandter CA; Kardar M; Sengupta S; Sivaloganathan S
Comput Math Methods Med; 2011; 2011():790721. PubMed ID: 21461349
[TBL] [Abstract][Full Text] [Related]
4. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
Li X; Wu M; Pan L; Shi J
Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
[TBL] [Abstract][Full Text] [Related]
5. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Dalal S; Burchill SA
Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
[TBL] [Abstract][Full Text] [Related]
7. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of recombinant human TNF in human cancer therapy.
Lejeune FJ; Liénard D; Matter M; Rüegg C
Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide.
Wietrzyk J; Boratynski J; Grynkiewicz G; Ryczynski A; Radzikowski C; Opolski A
Anticancer Res; 2001; 21(6A):3893-6. PubMed ID: 11911265
[TBL] [Abstract][Full Text] [Related]
10. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor vascular compartment to improve conventional cancer therapy.
Feron O
Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
[TBL] [Abstract][Full Text] [Related]
12. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
13. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz JL
Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
[TBL] [Abstract][Full Text] [Related]
16. Targeting the molecular basis for tumour hypoxia.
Carroll VA; Ashcroft M
Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
[TBL] [Abstract][Full Text] [Related]
17. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
19. Suppression of angiogenesis and tumour progression by combretastatin and derivatives.
Sherbet GV
Cancer Lett; 2017 Sep; 403():289-295. PubMed ID: 28688972
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
